REG - PureTech Health PLC - Results of AGM on June 16, 2025 – Update Statement

Puretech HealthAnnouncement

Wed 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251210:nRSJ0866La&default-theme=true

RNS Number : 0866L  PureTech Health PLC  10 December 2025

10 December 2025

PureTech Health plc

 

Results of Annual General Meeting on June 16, 2025 - Update Statement

 

In accordance with Provision 4 of the UK Corporate Governance Code, PureTech
("PureTech" or the "Company") today provides an update in respect of the
results of its Annual General Meeting (AGM) held on June 16, 2025. While all
resolutions were approved by shareholders, more than 20% of votes were cast
against Resolutions 2 and 9, relating to the Directors' Remuneration Report
and the re-election of Ms. Mazumdar-Shaw as a Director, respectively.

 

Building on prior year practice, and consistent with the Company's commitment
to maintaining constructive, transparent dialogue with its shareholders, the
Company has continued to actively engage with shareholders throughout 2025.
Since the 2025 AGM, the Board has taken further steps to understand the views
of shareholders. Specifically, the Company wrote to shareholders representing
approximately two-thirds of the Company's issued share capital 1  to offer
engagement with the Chair of the Board. Following that initial outreach,
meetings were held with shareholders representing nearly 50% of issued share
capital(1) during the month of July. While a range of topics was discussed,
shareholders provided feedback encouraging the Company to focus on alignment
with UK remuneration principles, while recognizing the challenges associated
with operating as a US-based company. Following these engagements, the
Remuneration Committee has reviewed the Company's remuneration practices,
including the quantum of equity grants for management. Full details of the
Remuneration Committee's decisions will be disclosed in the 2025 Annual Report
and Accounts, to be published in 2026.

 

With respect to the re-election of Ms. Mazumdar-Shaw, the Board believes that
she contributes significant value to the Company, while acknowledging the
scheduling conflict that impacted her attendance at Board meetings in 2024.
The Company notes that the scheduling conflict impacting attendance was
administrative in nature and is committed to implementing appropriate measures
to ensure optimal Director attendance at Board meetings going forward.

 

The Board would like to thank the shareholders who have engaged with the
Company during this process. The Board will continue to engage openly and
constructively with shareholders as it continues to develop the Company's
approach to governance, remuneration and reporting in the periods ahead.

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to remuneration practices and
decisions, future disclosures, and to our future prospects, developments and
strategies. The forward-looking statements are based on current expectations
and are subject to known and unknown risks, uncertainties and other important
factors that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not limited to,
those risks, uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the year ended
December 31, 2024, filed with the SEC and in our other regulatory filings.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement speaks
only as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

 

 1  Based on the issued share capital as of July 25, 2025.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEAXAEFDDSFFA



            Copyright 2019 Regulatory News Service, all rights reserved